First-Line Carboplatin, Pemetrexed, and Panitumumab in Patients with Advanced Non-Squamous KRAS Wild Type (WT) Non-Small-Cell Lung Cancer (NSCLC)
Article
Spigel, David R., Mekhail, Tarek M., Waterhouse, David, Hadley, Terence, Webb, Charles, Burris, Howard A., Hainsworth, John D., Greco, F. Anthony
funding text
This work was supported in part by a grant from Amgen.
abstract
Background: We added panitumumab to standard combination chemotherapy as first-line treatment for patients with advanced KRAS WT non-squamous NSCLC. Methods: Patients received panitumumab 9 mg/kg IV, pemetrexed 500 mg/m(2) IV, and carboplatin AUC = 6 IV every 21days. After 6 cycles, maintenance therapy with panitumumab and pemetrexed was administered every 21days until progressive disease or unacceptable toxicity. Results: 29 of 66 patients (44%) had objective responses. The median TTP was 6 months; median overall survival (OS) was 17 months. Panitumumab increased treatment-related toxicity, notably skin rash. Conclusions: The addition of panitumumab increased toxicity, and had no discernible impact on efficacy.